Intravitreal bevacizumab (Avastin) vs. ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a systematic review.
about
Aflibercept for neovascular age-related macular degenerationAflibercept for neovascular age-related macular degenerationSystemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degenerationAnti-vascular endothelial growth factor for neovascular age-related macular degenerationSystemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degenerationA retrospective, pooled data analysis of the safety of pegaptanib sodium in the treatment of age-related macular degeneration in subjects with or without diabetes mellitusSystemic adverse events after intravitreal bevacizumab versus ranibizumab for age-related macular degeneration: a meta-analysis.Interventions for Age-Related Macular Degeneration: Are Practice Guidelines Based on Systematic Reviews?Arterial thromboembolic events in patients with exudative age-related macular degeneration treated with intravitreal bevacizumab or ranibizumab.Time-course of sFlt-1 and VEGF-A release in neutropenic patients with sepsis and septic shock: a prospective studyEfficacy and safety of intravitreal therapy in macular edema due to branch and central retinal vein occlusion: a systematic review.Comparison of bevacizumab and ranibizumab in age-related macular degeneration: a systematic review and meta-analysis.A review of safety incidents in England and Wales for vascular endothelial growth factor inhibitor medications.Intraocular Pressure Changes in Non-Glaucomatous Patients Receiving Intravitreal Anti-Vascular Endothelial Growth Factor Agents.How the comparison of age-related macular degeneration treatments trial results will impact clinical careRetinal vascular changes following intravitreal ranibizumab injections for neovascular AMD over a 1-year period.The use of comparative effectiveness research to inform policy decisions on the inclusion of bevacizumab for the treatment of macular diseases in Thailand's pharmaceutical benefit package.Effects of multiple intravitreal anti-VEGF injections on retinal nerve fiber layer and intraocular pressure: a comparative clinical study.Nanoparticles in porous microparticles prepared by supercritical infusion and pressure quench technology for sustained delivery of bevacizumab.Drug delivery strategies for therapeutic angiogenesis and antiangiogenesis.Translating research into practice.Effect of the Honan intraocular pressure reducer on intraocular pressure increase following intravitreal injection using the tunneled scleral technique.
P2860
Q24186157-43CEE81D-F944-476D-90A8-D15480CAAE2AQ24193255-2BD2F3EF-27FE-4109-9A10-870BEA84BAF5Q24193614-383EC054-7575-46B0-A9AD-39B5E94456D4Q24194251-6B2F2953-543B-416A-8D99-B12C0DF1B44AQ24195003-824427AE-85AC-4F82-A24A-C6417694005AQ34370043-A198D2C1-C04F-4353-8A15-DA53C1139CD2Q34444212-490C4876-E3DC-4C63-8C47-9ED99FC06B3EQ34510579-87B8178C-5EBF-4FE5-8352-6D7940F7E7A7Q34627103-F365900A-A254-4147-AB64-90755D7434B9Q34677335-A1916705-8B14-41A4-B47E-3A3D70385288Q35036495-5FF21D09-13BC-4C5B-B098-A26A93EAF6EDQ35162123-0FE4A5AE-E11B-4303-BF3E-7C9F910D90C0Q35226722-0171B2D0-5063-4B2C-A828-DA6FB8B1BB01Q35770567-E7B7F14D-8B27-4B74-9BD4-5BB17FEBA6C8Q36025168-6A0D0EB5-419B-48F4-9A67-6270041AB24CQ36093275-99562059-FED3-43BE-880F-34ADFAACDB43Q36461851-C515EFCB-FC9F-4296-A2A6-0E8036A068F9Q36788545-34650493-7873-43CA-ADB7-E16566C7BB39Q37731143-E01E8BDC-EFA3-417D-B601-36F68EFD1143Q37845396-F99376AB-9FBD-4D03-8B71-7E5F99AE79E4Q42409934-076CA72E-050C-4ADB-8758-60F73DE61D3AQ48228197-FEEA3057-5763-4CD5-AA52-3677B801FA11
P2860
Intravitreal bevacizumab (Avastin) vs. ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a systematic review.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Intravitreal bevacizumab (Avas ...... neration: a systematic review.
@en
type
label
Intravitreal bevacizumab (Avas ...... neration: a systematic review.
@en
prefLabel
Intravitreal bevacizumab (Avas ...... neration: a systematic review.
@en
P2093
P1476
Intravitreal bevacizumab (Avas ...... neration: a systematic review.
@en
P2093
Christoph Ehlken
Gerd Antes
Hansjuergen T Agostini
Lutz L Hansen
Monika Lelgemann
P304
P356
10.1097/ICU.0B013E3283386783
P577
2010-05-01T00:00:00Z